drugset
drugset / Trial / NCT01454349

Study of PRX302 for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia (BPH)

NCT01454349 ↗

Phase 1/2 Completed 40 enrolled Sophiris Bio Corp
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the safety, tolerability and efficacy of a single treatment of PRX302 for the treatment of Benign Prostatic Hyperplasia (BPH) as compared to placebo.

Timeline

Start
2011-09
Primary completion
2013-03
Completion
2013-08

Drugs

EvaluationDrugModalityDoseRoute
Subject TOPSALYSIN Unknown 0.75 ug/ml Other
Subject TOPSALYSIN Unknown 1.5 ug/ml Other
Subject TOPSALYSIN Unknown 3 ug/ml Other
Subject TOPSALYSIN Unknown 6 ug/ml Other

Indications

benign prostatic hyperplasia